MCM
RNTX

Masters Capital Management’s Rein Therapeutics RNTX Stock Holding History

Masters Capital Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,500
Closed -$401K – 84
2017
Q3 		$401K Hold
1,500
– – 0.01% 65
2017
Q2 		$335K Buy
+1,500
New +$329K 0.01% 66

Other funds holding RNTX

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Masters Capital Management's RNTX Position: Q4 2017 in Review

Masters Capital Management sold out of Rein Therapeutics (RNTX) in Q4 2017, closing a stake of 1,500 shares — an estimated $401K sold.

Masters Capital Management first reported a position in RNTX in Q2 2017 and held it in 2 quarters. The position peaked at $401K in Q3 2017. 33 funds tracked by Wall St. Rank hold RNTX as of Q4 2017.

  • Masters Capital Management reported no remaining Rein Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Masters Capital Management sold 1,500 Rein Therapeutics shares in Q4 2017, an estimated $401K.
  • Masters Capital Management first reported a position in Rein Therapeutics in Q2 2017 and held it in 2 quarters.
  • Masters Capital Management's Rein Therapeutics position peaked at $401K in Q3 2017.
  • 33 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2017.

Based on Masters Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.